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MortalityAbstract Background: Acute exacerbations of chronic obstructive pulmonary disease (AECOPD)
impose a considerable burden of morbidity, mortality, and health care cost and frequently require
hospital admission. Clinicians lack a validated tool for risk stratiﬁcation of such admissions.
Aim: To ﬁnd the best prognostic score for prediction of in-hospital mortality due to AECOPD
by comparing between the DECAF, the modiﬁed DECAF, the BAP-65 and the 2008 scores.
Methods: 264 patients admitted to Chest Department, Menouﬁa University Hospitals for
management of AECOPD were included; either retrospectively from January 2014 to February
2015 or prospectively from March to September 2015. The 4 scores were calculated for each of them.
Results: Twenty patients (7.58%) died during their hospital stay. The non-surviving group had a
statistically signiﬁcant higher age, all were males and 19 of them were smokers. The DECAF score
had an area under receiver-operating characteristic curve (AUROC) of 0.828, its sensitivity was
0.8, while its speciﬁcity was 0.623. The AUROC of the modiﬁed DECAF score was 0.774, its sensi-
tivity and speciﬁcity were 0.8 and 0.443 respectively. The BAP score had the highest AUROC (0.861),
its sensitivity and speciﬁcity were 0.8 and 0.951 respectively. The 2008 score had an AUROC of 0.774,
its sensitivity and speciﬁcity were 1 and 0.279 respectively.
Conclusion: BAP-score had higher AUROC and was more accurate in predicting in-hospital mor-
tality than DECAF, modiﬁed DECAF and the 2008 scores.
 2016 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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Acute exacerbations of chronic obstructive pulmonary disease
(AECOPD) are major events in the long-term course of the
disease since their repetition is associated with impaired lungfunction, health status and survival and markedly increased
health care costs [1]. On the short term, they impair often nota-
bly health status and expose to risks of acute respiratory fail-
ure and death. Home-based care has been shown to
represent a valuable alternative for many patients visiting
emergency departments (EDs), allowing to avoid or shorten
hospital stays [2]. However, most patients with AECOPD vis-
iting EDs are hospitalized. In that context, assessing the sever-
ity of AECOPD is mandatory to guide decisions of orientation
(home, hospital medical ward or intensive care unit) as well as
Table 1 DECAF score [6].
Variable Score
Dyspnoea eMRCD 5a 1
eMRCD 5b 2
Eosinopenia (<0.05 3109/l) 1
Consolidation 1
Acidaemia (pH < 7.3) 1
Atrial ﬁbrillation 1
Total DECAF score 6
DECAF, dyspnoea, eosinopenia, consolidation, acidaemia and
atrial ﬁbrillation; eMRCD, extended MRC dyspnoea.
Table 2 Modiﬁed DECAF score [7].
Variable Score
Dyspnoea eMRCD 5a 1
eMRCD 5b 2
Eosinopenia (<0.05 3109/l) 1
Consolidation 1
Acidaemia (pH < 7.3) 1
Frequency of admission in AECOPD in last year (P2) 1
Total modiﬁed DECAF score 6
Modiﬁed DECAF, dyspnoea, eosinopenia, consolidation,
acidaemia and frequency of admission; eMRCD, extended MRC
dyspnoea.
Table 3 BAP-65 score [8].
Variable Point
BUN> 25 or Urea > 9 1
Altered mental status 1
Pulse > 109 beats/min 1
Age > 65 years 1
Total score 4
Table 4 2008 score [9].
Variable Point
Age <70 years 0
P70 years 1
MRC (baseline, steady state) 0–1 0
2–3 1
4–5 2
Number of signs of severity* at entry 0 0
1–2 2
3 and more 3
Total score 6
* Signs of severity: cyanosis, use of accessory inspiratory muscles,
paradoxical abdominal movement, asterixis, neurological impair-
ment, lower limb edema.
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after acute episode [3] (see Tables 1–4).
In stable COPD, prognostic indices have been thoroughly
investigated and tools predicting mortality risk, such as the
BODE Score, are well established [4]. However, prognostic
research in exacerbations requiring hospitalization has been
limited, and there appears to be little common ground between
predictors of mortality in stable disease and during AECOPD
[5].
Recently, few clinical scores were developed to assess the
severity of AECOPD aiming to help clinicians in their deci-
sions regarding patients suffering such episodes [6–9]. Hence,
the aim of this work was to compare the prognostic value of
the DECAF score, the modiﬁed DECAF score, the BAP 65
score and the 2008 score in predicting in-hospital mortality
of patients with AECOPD to help in planning of proper man-
agement protocols.
Methods
In this study, a total of 264 patients admitted to Chest Depart-
ment, Menouﬁa University Hospitals for management of
AECOPD were included; either retrospectively (174 patients)
by reviewing the hospital’s records during the period from
January 2014 to February 2015 or prospectively (90 patients)
during the period from March to September 2015. The
recruited patients were those who had complete data regarding
the required score items and matched the inclusion criteria.
The total patients recruited were 176 males and 88 females
with age ranging between 40 and 89 years.The diagnosis of AECOPD was according to Global
Initiative for Chronic Obstructive Lung Disease (GOLD) crite-
ria supported by spirometric evidence of airﬂow obstruction
(forced expiratory volume in one second (FEV1)/forced vital
capacity (FVC) < 0.70) when clinically stable [10], while
an exacerbation of COPD was deﬁned as an acute event
characterized by a worsening of the patient’s respiratory symp-
toms that is beyond normal day-to-day variations and leads to
a change in medication [11,12]. Exclusion criteria were:
domiciliary ventilation, comorbidity expected to limit survival
to less than 12 months (as metastatic malignancy) or primary
reason for admission other than AECOPD. Informed consents
were obtained from patients in the prospective part of the
study and ethics approval was obtained from the Menouﬁa
University Hospital’s Review Board before data collection.
The collected data included age, sex, smoking, and assess-
ment of stable state dyspnea grade over the preceding
3 months based on the extended Medical Research Council
Dyspnea Score (eMRC) [13], in addition to admission data
regarding: clinical examination including assessment of mental
state conscious level and signs of severity of exacerbation
(cyanosis, use of accessory inspiratory muscles, paradoxical
abdominal movement, asterixis, neurological impairment,
lower limb edema), chest radiological examination, ECG,
arterial blood gases analysis, measurement of blood urea
nitrogen (BUN), complete blood count (CBC). Severity scores
for AECOPD were calculated for each patient, which are:
DECAF [6], modiﬁed DECAF [7], BAP-65 [8] and 2008 score
[9]. Patients were managed according to their condition
and prognosis was recorded, either recovery and discharge or
in-hospital mortality.
Statistical analysis was performed with the SPSS statistical
software package version 14 (SPSS Inc., Chicago, IL, USA).
Student’s T test was used to compare means. Chi square test
Table 5 Comparison between survivors and non-survivors regarding demographic data.
Variable Survivors (N= 244) Non-survivors (N= 20) p-Value
Age (years) mean ± SD 63.61 ± 11.16 72.8 ± 8.57 0.012
Sex Males (n= 176) 156 20 0.014
Females (n= 88) 88 0
Smoking habit Yes (n= 163) 144 19 0.003
No (n= 101) 100 1
Table 6 Statistical correlation between mortality and demo-
graphic data.
Variable Correlation coeﬃcient (R) p-Value
Age 0.217 0.013
Sex 0.202 0.02
Smoking habit 0.371 0.018
Figure 1 ROC curve for DECAF score.
Figure 2 ROC curve for modiﬁed DECAF score.
COPD in-hospital mortality scores 581(v2) was used to compare two qualitative variables. Pearson
correlation was used to study the association between vari-
ables. Area under receiver-operating characteristic curve
(AUROC) was used to calculate sensitivity and speciﬁcity. A
p-value of <0.05 was considered statistically signiﬁcant.
Results
This study included 264 patients in AECOPD, their mean age
was 64.3 ± 11.23 years. They were 176 (66.7%) males and 88
(33.3%) females. One hundred sixty-three patients (66.8%)
were current or ex-smokers. Twenty patients (7.58%) died
during their hospital stay.
The mean age of the surviving patients was 63.61
± 11.16 years, while the mean age of the non-survivingpatients was 72.8 ± 8.57 years with a signiﬁcant difference
between both groups (p= 0.012). All the 20 patients who died
were males and 19 of them were smokers (Table 5). There was
a signiﬁcant correlation between each of age, smoking habit
and male sex of the patients and mortality. (p= 0.013 and
0.02 respectively) (Table 6).
The DECAF score had an area under receiver-operating
characteristic curve (AUROC) of 0.828 (Fig. 1), its sensitivity
was 0.8, while its speciﬁcity was 0.623. The AUROC of the
modiﬁed DECAF score was 0.774 (Fig. 2), its sensitivity and
speciﬁcity were 0.8 and 0.443 respectively. The BAP score
had the highest AUROC (0.861) (Fig. 3), its sensitivity and
speciﬁcity were 0.8 and 0.951 respectively. The 2008 score
had an AUROC of 0.774 (Fig. 4), its sensitivity and speciﬁcity
were 1 and 0.279 respectively (Table 7).
Discussion
Despite AECOPD being considered both common and often
fatal, accurate prognostication of patients hospitalized with
an exacerbation is difﬁcult [6]. In stable COPD, prognostic
indices have been thoroughly investigated and tools predict-
ing mortality risk, such as the BODE score [4], are well
established. However, prognostic research in exacerbations
Figure 3 ROC curve for BAP-65 score.
Figure 4 ROC curve for 2008 score.
Table 7 Statistical comparison between the studied severity
scores regarding AUROC curve, sensitivity and speciﬁcity.
Severity score DECAF Modiﬁed
DECAF
BAP-65 2008
score
AUROC curve 0.828 0.774 0.861 0.774
Sensitivity 0.8 0.8 0.8 1
Speciﬁcity 0.623 0.443 0.951 0.279
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to be little common ground between predictors of mortality
in stable disease and during AECOPD [5]. Furthermore, none
of the prognostic tools developed in stable disease have been
tested on hospitalized patients, and most require clinical mea-
surements not routinely available at hospital admission [6]. A
number of severity scores of AECOPD have been developed
and are being used to predict the in-hospital mortality from
that condition [6–9]. In this study, we tried to compare
between four of them, namely the DECAF, the modiﬁedDECAF, the BAP-65 and the 2008 scores in the aim for
ﬁnding the best prognostic score with the best sensitivity and
speciﬁcity for prediction of the in-hospital mortality during
the acute exacerbation.
This study included 264 patients hospitalized for
AECOPD. Their mean age was 64.3 ± 11.23 years. They were
176 (66.7%) males and 88 (33.3%) females. During the hospi-
tal stay, 20 (7.58%) patients died. This mortality rate matches
with published ﬁgures; as it was published that in-hospital
mortality of 4–30% has been reported in patients with
AECOPD requiring hospitalization [6,14,15]. The variability
in published mortality rates for patients with COPD admitted
for acute respiratory failure suggests that signiﬁcant hetero-
geneity exists within this population. It is likely that differences
in patient characteristics, more than in quality of care, account
for much of the variability. The relatively small size of many of
the studies makes them more susceptible to these considera-
tions [16]. When comparing between surviving and non-
surviving patients, we found that the non surviving group
had a statistically signiﬁcant higher age (p= 0.012). We also
found a signiﬁcant correlation between age and mortality
(Tables 5 and 6). COPD is a known disease of old age and
its severity increases with the duration of exposure, also,
morbidity due to COPD increases with age [17]. In their study
on 1824 AECOPD patients, Roche et al. [18] found that age is
an independent risk factor for in-hospital mortality.
We found that the 20 non-surviving patients were all males
and 19 of them were smokers. Male sex and smoking habit had
a signiﬁcant correlation with mortality (Tables 5 and 6). In our
locality, female smoking is minimal, so, most COPD in females
is due to causes other than smoking. This may explain the
milder form of the disease in females, as it was found that
cigarette smokers have a higher prevalence of respiratory
symptoms and lung function abnormalities, a greater annual
rate of decline in FEV1 and a greater COPD mortality rate
than nonsmokers [19]. Moreover, morbidity due to COPD is
greater in men than women [17].
When we compared between the area under the ROC curve
among the 4 studied scores, we found that the highest AUROC
curve was that of the BAP-65 score (0.861). It had also the
highest speciﬁcity (0.951). The highest sensitivity was found
in the 2008 score [6] (1), yet it had a low sensitivity (0.279)
(Table 5 and Figs. 1–4).
The ideal scoring system should be sensitive, speciﬁc for the
disease, easy to perform and in this condition should be readily
available on admission to facilitate the quick decision regard-
ing the patient‘s management and risk stratiﬁcation.
Steer et al. [6] developed the DECAF score. They found
that it had AUROC curve for prediction of 30 day mortality
of 0.82 and in the subgroup of patients with consolidation, it
was a stronger predictor than CURB-65 (AUROC= 0.75
vs. 0.64, p= 0.003).
COPD in-hospital mortality scores 583Steer et al. [6] compared their score with the 2008 score
derived by Roche et al. [9], they stated that the 2008 score
showed good discrimination for in-hospital mortality
(AUROC= 0.79) but included subjectively assessed signs of
clinical severity and that the DECAF Score performed more
strongly in their population than the tool described by Roche
et al. in its derivation cohort and, furthermore, the prognostic
indices included in the DECAF score are objective with little
potential for variable interpretation. This may explain the low
speciﬁcity of the 2008 score that we found in our study. However,
Roche et al. [18] validated their score which is based on age, base-
line dyspnea grade and number of signs of severity on another
population of hospitalized AECOPD patients and they found
that their score was reliable in this population as it was in the orig-
inal population on whom it was derived (emergency department
patients) and that it had AUROC= 0.77, sensitivity = 69%
and speciﬁcity = 76%. They claimed that adding biological or
imaging variables, as in DECAF, might improve the predictive
capacity of the scoring systems, but, this would compromise their
use in the community setting and even in the hospital awaiting
their results could delay the score based decisions.
Nafea et al. [20] carried out a study on 200 AECOPD
patients, they illustrated that the DECAF score showed an
excellent discrimination for in-hospital mortality
(AUROC= 0.83). Furthermore, the DECAF Score per-
formed signiﬁcantly better for the prediction of in-hospital
mortality than: the Acute Physiology and Chronic Health
Evaluation (APACHE) II prognostic index (AUROC= 0.68,
DECAF vs. APACHE II, p= 0.03); and the COPD and
Asthma Physiology Score (CAPS) (AUROC= 0.65,
p= 0.01); which have been proposed as useful predictive
instruments in AECOPD. They also found that the DECAF
score was a signiﬁcantly stronger predictor of in-hospital mor-
tality than CURB-65 for a subgroup of patients with radiolog-
ical consolidation (AUROC= 0.87 vs. 0.65, p= 0.02).
Zidan et al. [7] tried to replace the atrial ﬁbrillation item in the
DECAF score (which has no signiﬁcant value (p= 0.618)) to
mortality by the frequency of admission (which has a signiﬁcant
relation to the mortality (p< 0.001), and they called the new
score Modiﬁed DECAF score (dyspnea, eosinopenia, consolida-
tion, respiratory acidosis and frequency of admission). There were
signiﬁcant values (p< 0.001) between the modiﬁed DECAF
score and mortality due to AECOPD. They concluded that the
Modiﬁed DECAF score is more sensitive and more speciﬁc in
predicting in-hospital mortality in acute exacerbation of COPD
than the DECAF score with no signiﬁcant difference between
the two scores. They found that the AUROC curve was 0.848
vs. 0.874 for the DECAF score vs. the modiﬁed DECAF score
respectively. In our study, we found the AUROC for the DECAF
and the modiﬁed DECAF equal to 0.828 and 0.774 respectively.
The BAP-65 score developed by Shorr et al. [8] depends on
age, altered mental status, pulse and one laboratory marker
which is the BUN. They found that it had AUROC= 0.77
and it correlated well with multiple clinical outcomes ranging
from in-hospital mortality and need for mechanical ventilation
to length of stay and cost. They claimed also that the BAP-65
score also identiﬁed subjects unlikely to ever need mechanical
ventilation. The BAP-65 has the advantages of being simple,
easy to calculate without sophisticated analysis of multiple fac-
tors that represent disease severity into a separate variable, as
in 2008 score, it also lacks subjective variables as dyspnea. The
BAP-65 includes one laboratory marker which is BUN whichmakes it easier in application than the DECAF and the mod-
iﬁed DECAF.
Conclusion
BAP-score had higher AUROC and was more accurate in pre-
dicting in-hospital mortality in patients with AECOPD than
DECAF, modiﬁed DECAF and the 2008 scores. Further trials
are needed to develop a better prognostic scoring system for
AECOPD patients.
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